Patents by Inventor Su-Lin Lee

Su-Lin Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Power saving techniques for layer-to-layer interface
    Patent number: 12225468
    Abstract: A method includes: receiving, at a first layer of a protocol stack, multiple code blocks from a base station, the multiple code blocks is a portion of a transport block and is associated with an error rate; transmitting, to a second layer of the protocol stack, the multiple code blocks; and determining, at the second layer and based on the error rate, whether to (1) store the multiple code blocks in memory or (2) process the multiple code blocks. A method for saving power in a physical (PHY) layer-to-medium access (MAC) layer interface and a network device, and a system are also provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 11, 2025
    Assignee: GREATER SHINE LIMITED
    Inventors: Tianan Tim Ma, Su-Lin Low, Hausting Hong, Chun-I Lee, Jianzhou Li, Hong Kui Yang, Xiaoshu Qian, Jian Gu, Chenxi Wang
  • Integrin-linked kinase inhibitors
    Patent number: 8658647
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
  • INTEGRIN-LINKED KINASE INHIBITORS
    Publication number: 20120142702
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 7, 2012
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp